Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Genitourinary 1

Conditions

Carcinoma, Transitional Cell 7Urinary Bladder Neoplasms 4Ureteral Neoplasms 2Urologic Neoplasms 1Urethral Neoplasms 1Peripheral Nervous System Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1Carcinoma in Situ 1

Interventions

enfortumab vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Urothelial Cancer and Other Malignant Solid Tumors × enfortumab vedotin × Clear all
NCT02091999 2024-11-01

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Astellas Pharma Inc

Phase 1 Completed
213 enrolled
GenitourinaryOther solid neoplasm

Metastatic Urothelial Cancer and Other Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡